No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
FATE Fate Therapeutics
- 3.800
- -0.070-1.81%
Close Apr 26 16:00 ET
- 3.880
- +0.080+2.11%
Post 17:42 ET
432.38MMarket Cap-2317P/E (TTM)
3.950High3.740Low2.73MVolume3.880Open3.870Pre Close10.39MTurnover2.96%Turnover RatioLossP/E (Static)113.78MShares8.83052wk High1.17P/B351.38MFloat Cap1.63052wk Low--Dividend TTM92.47MShs Float121.160Historical High--Div YieldTTM5.43%Amplitude1.460Historical Low3.801Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Fate Therapeutics Currently Down 11 Consecutive Days, on Track for Record Losing Streak -- Data Talk
Fate Therapeutics, Inc. (FATE) is currently at $4.36, down $0.18 or 3.96% --Would be lowest close since Jan. 18, 2024, when it closed at $4.33 --Currently down 14 of the past 15 days --Currently do
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Danaher (DHR) and Roche Holding AG (OtherRHHVF)
Fate Therapeutics Currently Down 10 Consecutive Days, on Pace for Longest Losing Streak Since December 2022 -- Data Talk
Fate Therapeutics, Inc. (FATE) is currently at $4.58, down $0.21 or 4.29% --Would be lowest close since Jan. 26, 2024, when it closed at $4.56 --Currently down 13 of the past 14 days --Currently do
Express News | Wedbush Reiterates Neutral on Fate Therapeutics, Maintains $7 Price Target
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B Cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
Fate Therapeutics, Inc. (NASDAQ: FATE) today announced that two presentations will be featured at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, being held in Baltimore, Maryland on May 7-11, 2024.
Why Investors Shouldn't Be Surprised By Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Share Price Plunge
Fate Therapeutics, Inc. (NASDAQ:FATE) shares have retraced a considerable 28% in the last month, reversing a fair amount of their solid recent performance. The drop over the last 30 days has capped
Comments
Gear up for AACR24!
See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
9
$Fate Therapeutics(FATE.US$ Press Release: Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
Dow Jones· 1 min ago
Dow Jones· 1 min ago
Analysts downgrade revenue estimates for next year and reduce loss estimates. The company's revenue is expected to decline by 92% annually by end of 2024, a shift from historical growth of 47% over the last five years. Fate Therapeutics is expected to lag the wider industry.
Fate Therapeutics' P/S ratio aligns with peers due to predicted revenue drop in following years. Given forecasted revenue slide and below par industry growth, future share price gains may be minimal. It's vital to consider the company's future prospects and not just its P/S ratio when deciding to sell stock.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg